Week In Review: Junshi Out-Licenses Ex-China Rights For COVID-19 Therapeutic To Lilly

Junshi Biosciences out-licensed ex-China rights for a therapeutic antibody aimed at preventing and treating COVID-19 to Eli Lilly. Lilly plans to file an IND and start trials in the US in Q2 of 2020.